Astrazeneca

FromAstraZeneca ([email protected])
Subject (42)KOMET Phase III trial met primary endpoint
Preheader (150)Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in glo
Typography
Arial
Colors
Text Analysis
Body Words246
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px816 px
X-Spam Score3.0
Preheader OptimizedNo
Timing
Day of WeekTuesday
TimeEarly Morning

KOMET Phase III trial met primary endpoint

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in glo
KOMET Phase III trial met primary endpoint